Tag: regulatory statistics

Minimization and Dynamic Allocation: Pros, Cons and Regulatory Concerns

November 17, 2025November 15, 2025 digi

Minimization and Dynamic Allocation: Pros, Cons and Regulatory Concerns Minimization and Dynamic Allocation: Pros, Cons and Regulatory Concerns In clinical trials, maintaining the integrity and validity of results is paramount. A critical component of achieving this is the randomization process, which mitigates biases and balances treatment across various groups. This guide explores minimization and dynamic…

Randomization Lists & IAM

Centralized Randomization Through IRT/IVRS Systems: Design and Controls

November 17, 2025November 15, 2025 digi

Centralized Randomization Through IRT/IVRS Systems: Design and Controls Centralized Randomization Through IRT/IVRS Systems: Design and Controls In the realm of clinical trials, the effective management of randomization is crucial for ensuring the integrity of the study’s results. Centralized randomization via Interactive Response Technology (IRT) and Interactive Voice Response Systems (IVRS) has emerged as a vital…

Randomization Lists & IAM

Stratified and Blocked Randomization: When and How to Use Them

November 17, 2025November 15, 2025 digi

Stratified and Blocked Randomization: When and How to Use Them Stratified and Blocked Randomization: When and How to Use Them Randomization is a cornerstone of clinical trials, ensuring that treatment groups are comparable and that any observed effects can be attributed to the interventions being tested rather than confounding factors. Among various randomization techniques, stratified…

Randomization Lists & IAM

Implementing IAM (Interactive Allocation Methods) in Modern Clinical Trials

November 17, 2025November 15, 2025 digi

Implementing IAM (Interactive Allocation Methods) in Modern Clinical Trials Implementing IAM (Interactive Allocation Methods) in Modern Clinical Trials Introduction to Interactive Allocation Methods (IAM) Clinical trials play a crucial role in the advancement of medical science and the development of new treatments, particularly in fields such as oncology. With the rising complexity and volume of…

Randomization Lists & IAM

Randomization Lists That Protect Trial Integrity and Regulatory Confidence

November 17, 2025November 15, 2025 digi

Randomization Lists That Protect Trial Integrity and Regulatory Confidence Randomization Lists That Protect Trial Integrity and Regulatory Confidence In the realm of clinical research, maintaining the integrity of a trial is paramount. Randomization lists play a crucial role in ensuring unbiased assignment of participants to treatment groups, and they can significantly influence regulatory confidence. This…

Randomization Lists & IAM

Case Studies: Underpowered vs Robustly Powered Clinical Programs

November 17, 2025November 15, 2025 digi

Case Studies: Underpowered vs Robustly Powered Clinical Programs Case Studies: Underpowered vs Robustly Powered Clinical Programs In clinical research, the significance of adequate sample size and power calculations cannot be overstated. Studies that are underpowered risk false negatives, hampering scientific discovery and regulatory approval, whereas robustly powered clinical programs enhance reliability and validation. This tutorial…

Sample Size & Power Calculations

Case Studies: Underpowered vs Robustly Powered Clinical Programs

November 17, 2025December 30, 2025 digi

Case Studies: Underpowered vs Robustly Powered Clinical Programs Conducting robust clinical trials requires meticulous planning and a profound understanding of statistical principles, particularly sample size and power calculations. This article aims to guide clinical operations, regulatory affairs, and medical affairs professionals in the US, UK, and EU through a detailed exploration of the implications of…

Sample Size & Power Calculations

Global Regulatory Expectations for Sample Size Justification

November 17, 2025November 15, 2025 digi

Global Regulatory Expectations for Sample Size Justification Global Regulatory Expectations for Sample Size Justification The determination of an appropriate sample size is a critical aspect of clinical trial design. It ensures that study findings are both statistically significant and clinically meaningful. Regulatory bodies across the US, UK, and EU provide guidelines that outline how sample…

Sample Size & Power Calculations

Using External and Real-World Data to Inform Sample Size Planning

November 17, 2025November 15, 2025 digi

Using External and Real-World Data to Inform Sample Size Planning Effective sample size planning is crucial for the success of clinical trials, particularly when aiming to meet regulatory expectations from entities such as the FDA, EMA, and MHRA. This guide provides a step-by-step tutorial on how to leverage external and real-world data to inform sample…

Sample Size & Power Calculations

Sample Size Strategies for DCT, Hybrid and Pragmatic Clinical Trials

November 17, 2025November 15, 2025 digi

Sample Size Strategies for DCT, Hybrid and Pragmatic Clinical Trials Sample Size Strategies for DCT, Hybrid and Pragmatic Clinical Trials In the evolving landscape of clinical research, innovative methodologies such as decentralized trials (DCT), hybrid trials, and pragmatic trial designs require precise strategies for sample size calculation. These trials differ in their execution and objectives,…

Sample Size & Power Calculations